Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

An effusion-based presentation of ALK − anaplastic large cell lymphoma

Yue Zhao, Endi Wang

Blood (2021) 137 (18): 2563.

https://doi.org/10.1182/blood.2021011140

Published: 2021

Journal Articles

Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)

Yan Leyfman, BS, Erel Joffe, MDMSc, Esther Drill, PhD, Sridevi Rajeeve, MD, Andrew D. Zelenetz, MD PhD, Maria Lia Lia Palomba, Craig H. Moskowitz, Carol S. Portlock, MD, Ariela Noy, MD, Steven M. Horwitz, MD, Alison J. Moskowitz, MD, Paul A. Hamlin, MD, Matthew J Matasar, MD, Anita Kumar, MD, Gottfried R. von Keudell, MD PhD, Connie Lee Batlevi, MD PhD, Anas Younes, MD, David J. Straus, MD

Blood (2019) 134 (Supplement_1): 2826.

https://doi.org/10.1182/blood-2019-123257

Published: 2019

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

https://doi.org/10.1182/blood-2019-122070

Published: 2019

Journal Articles

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Anna Vanazzi, MD, Safaa Ramadan, PhD MD, Francesca De Lorenzi, MD, Paola Arena, MD, Enrico Derenzini, MD PhD, Mario Rietjens, Anna Rotili, MD, Antuono Latronico, MD, Laura Travaini, MD, Emanuela Omodeo Sale', Daniela Malengo, Marianna Gerardi, Stefano Fiori, MD, Valentina Tabanelli, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5283.

https://doi.org/10.1182/blood-2019-125239

Published: 2019

Journal Articles

Too big for flow

Carole Almire, Nicolas Chapuis

Blood (2019) 134 (6): 576.

https://doi.org/10.1182/blood.2019001172

Published: 2019

Journal Articles

Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma

Matias Mendeville, Margaretha G. M. Roemer, Mari F. C. M. van den Hout, G. Tjitske Los-de Vries, Reno Bladergroen, Phylicia Stathi, Nathalie J. Hijmering, Andreas Rosenwald, Bauke Ylstra, Daphne de Jong

Blood (2019) 133 (4): 377–380.

https://doi.org/10.1182/blood-2017-12-822171

Published: 2019

Includes: Supplemental data

Journal Articles

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)

Kelly J. Norsworthy, MD, Flora Mulkey, MS, Ashley F. Ward, MD, Donna Przepiorka, MDPhD, Albert B. Deisseroth, MD PhD, Ann T. Farrell, MD, Richard Pazdur, MD

Blood (2018) 132 (Supplement 1): 288.

https://doi.org/10.1182/blood-2018-99-117426

Published: 2018

Journal Articles

Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study

Beth Boulden Warren, MD MS, Dianne Thornhill, PhD, Jill Stein, MD, Michael Fadell, MD, Sharon Funk, DPT, Heidi D. Lane, DPT, Carolyn M. Bennett, MD MSc, Amy Shapiro, Michael Recht, MD PhD, Marilyn J Manco-Johnson, MD

Blood (2018) 132 (Supplement 1): 382.

https://doi.org/10.1182/blood-2018-99-117413

Published: 2018

Journal Articles

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Mehdi Hamadani, MD, Graham P. Collins, MB BS DPhil, Felipe Samaniego, MD, Alexander I Spira, MD, Andrew Davies, John Radford, MD FRCP, Paolo Caimi, MD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 928.

https://doi.org/10.1182/blood-2018-99-118198

Published: 2018

Journal Articles

IL-13 Expression Characterizes Effusions Associated with Primary Effusion Lymphoma but Not Other Disorders Caused By Kaposi Sarcoma Herpesvirus (KSHV)

Ramya Ramaswami, MBBS, MPH, Kathryn Lurain, MD MPH, Vickie Marshall, Nazzarena Labo, MD PhD, Anaida Widell, Matthew Lindsley, Mark N. Polizzotto, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2018) 132 (Supplement 1): 4137.

https://doi.org/10.1182/blood-2018-99-117668

Published: 2018

Journal Articles

Clinical Characteristics of Hemophagocytic Syndrome: 46 Cases Report and Literature Re-View

Weibin Zhuo, Ya Gao, MD, Chunyan Yang, Ying Xu, Yintian Zhang, Dongmao Zhu, Qifa Liu, MD, Baohong Ping

Blood (2018) 132 (Supplement 1): 5916.

https://doi.org/10.1182/blood-2018-99-114383

Published: 2018

Journal Articles

Biology and management of primary effusion lymphoma

Kazuyuki Shimada, Fumihiko Hayakawa, Hitoshi Kiyoi

Blood (2018) 132 (18): 1879–1888.

https://doi.org/10.1182/blood-2018-03-791426

Published: 2018

Journal Articles

Mature Analysis of the Prospective Oxford Down Syndrome (DS) Cohort Study: Timing and Clinical Impact of Preleukemic GATA1 Mutations and Lessons for Management of Newborns with DS

Irene Roberts, MD, Neha Bhatnagar, ND, Amelie Chaussade, MD, Laure Nizery, MD, Helen Richmond, RSCN, Natalina Elliott, PhD, Gemma Buck, BSc, Marlen Metzner, MSc, Alison Kennedy, MSc, Catherine Garnett, Kelly Perkins, PhD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath

Blood (2017) 130 (Supplement 1): 569.

https://doi.org/10.1182/blood.V130.Suppl_1.569.569

Published: 2017

Journal Articles

Human Herpes-Virus 6 Infection in Immunocompromised Patients after Chemotherapy and Autologous Stem Cell Transplantation

Tatiana I. Lobanova, MD, Dmitry S. Tikhomirov, PhD, Olga A. Gavrilina, MDPhD, Zalina T. Fidarova, MDPhD, Galina A. Kliasova, Vladimir A. Okhmat, Vera V. Troitskaya, MD PhD, Elena N. Parovichnikova, MD PhD, Valery Savchenko, MD PhD academician

Blood (2017) 130 (Supplement 1): 1013.

https://doi.org/10.1182/blood.V130.Suppl_1.1013.1013

Published: 2017

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

Journal Articles

Mechanism of Pax5 Down-Regulation and Its Function in Primary Effusion Lymphoma

Hiroki Goto, MD, PhD, Ryusho Kariya, PhD, Eriko Kudo, PhD, Seiji Okada, MD, PhD

Blood (2017) 130 (Supplement 1): 3791.

https://doi.org/10.1182/blood.V130.Suppl_1.3791.3791

Published: 2017

Journal Articles

Evaluation of Tumor Burden for Predicting Survival in Patients with Follicular Lymphoma Receiving First-Line R-CHOP Treatment: Comparison of Different Definition of GELF Criteria

Harumi Kato, MD, Naoyuki Tange, MD, Chisako Iriyama, MD PhD, Yuki Kojima, MD, Hirofumi Taji, MD PhD, Tomohiro Kinoshita, MD PhD, Yasushi Yatabe, MD PhD, Shigeo Nakamura, MD PhD, Kazuhito Yamamoto, MDPhD

Blood (2017) 130 (Supplement 1): 4063.

https://doi.org/10.1182/blood.V130.Suppl_1.4063.4063

Published: 2017

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients

Luigia Luciano, MD, Giorgina Specchia, MD, Bruno Martino, Vincenzo Accurso, MD, Marco Santoro, MD, Alessandra Malato, MD, Nicola Sgherza, Michele Pizzuti, MD, Fabio Stagno, MD PhD, Pellegrino Musto, MD, Attilio Guarini, MD, Fiorenza De Gregorio, MD, Santina Basile, MD, Fabrizio Pane, MD

Blood (2017) 130 (Supplement 1): 2905.

https://doi.org/10.1182/blood.V130.Suppl_1.2905.2905

Published: 2017

Journal Articles

Utility of D-Dimer LEVEL As a Marker for Differentiation Syndrome, Infection, and Death in ACUTE Promyelocytic Leukemia (APL)

Catherine R. Caprara, MSN, NP, Prachi Kharkhanis, Kathryn Sarah Simon, PA-C, Stephanie Debragga, Sheldon Bolds, Martha L. Arellano, MD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 5071.

https://doi.org/10.1182/blood.V130.Suppl_1.5071.5071

Published: 2017

NARROW

An effusion-based presentation of ALK − anaplastic large cell lymphoma

Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Too big for flow

Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)

Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

IL-13 Expression Characterizes Effusions Associated with Primary Effusion Lymphoma but Not Other Disorders Caused By Kaposi Sarcoma Herpesvirus (KSHV)

Clinical Characteristics of Hemophagocytic Syndrome: 46 Cases Report and Literature Re-View

Biology and management of primary effusion lymphoma

Mature Analysis of the Prospective Oxford Down Syndrome (DS) Cohort Study: Timing and Clinical Impact of Preleukemic GATA1 Mutations and Lessons for Management of Newborns with DS

Human Herpes-Virus 6 Infection in Immunocompromised Patients after Chemotherapy and Autologous Stem Cell Transplantation

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Mechanism of Pax5 Down-Regulation and Its Function in Primary Effusion Lymphoma

Evaluation of Tumor Burden for Predicting Survival in Patients with Follicular Lymphoma Receiving First-Line R-CHOP Treatment: Comparison of Different Definition of GELF Criteria

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients

Utility of D-Dimer LEVEL As a Marker for Differentiation Syndrome, Infection, and Death in ACUTE Promyelocytic Leukemia (APL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only